Number One Success Story

Peptisyntha prides itself on being involved with one of the most successful peptide projects that has emerged in the last decade.  Indeed, the expertise of Peptisyntha is best illustrated by the development of the manufacturing process for the well known eptifibatide, a cyclic heptapeptide with a disulfide bridge, as a result of a long term cooperation with Millennium Pharmaceuticals, Inc. (as successor to Cor Therapeutics, Inc).  Eptifibatide is the active ingredient of Integrilin® (eptifibatide for injection), a leading cardiovascular drug used in hospital settings.  Peptisyntha has successfully scaled up the manufacturing process under full cGMP conditions.  The process is now being used to produce commercial quantities of bulk eptifibatide well in excess of 100 kg per year.

Large Scale Synthesis

There are numerous examples of peptides that have been produced by Peptisyntha on a relatively large scale.   Confidentiality agreements prevent us from disclosing specific examples.  However, there are well known families of peptides where Peptisyntha has developed an extensive experience, such as LHRH agonists, LHRH antagonists, angiotensin analogues …   Over the years, we have also handled peptides with many unusual amino acids, amino acids with modified side-chains as well as non natural amino acids (including D amino acids).  

Although the focus of Peptisyntha is strongly on peptide chemistry, some large scale projects involve the derivatization of either the N-terminal or the C-terminal end of the sequence for further coupling with non peptidic chemical entities.

Some more unusual examples

The R&D teams of Peptisyntha have successfully produced some difficult peptides, for example peptides with multiple cystine bridges.  

Peptisyntha has also a specific experience with peptidomimetics.   Also, a specific know how has been developed to conjugate peptides with protein carriers through specific linkers, leading to synthetic peptide based vaccines for human or veterinary applications.